In 2017, Toshihiko Doi (38) and Toshihiro Kudo (29) released their respective clinical trial results, which respectively demonstrated that Pembrolizumab and Nivolumab had certain anti-tumor effect in PD-L1(+) patients who failed second-line or back-like treatment. Here, CD274 is linked to neoplasm.